PJP:NYE-Invesco Dynamic Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 87.48

Change

-0.53 (-0.60)%

Market Cap

N/A

Volume

4.80K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.39 (-0.26%)

USD 40.46B
FHLC Fidelity® MSCI Health Care In..

-0.27 (-0.38%)

USD 2.91B
FXH First Trust Health Care AlphaD..

-0.07 (-0.06%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-1.55 (-1.68%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.24 (-0.97%)

USD 0.15B
SBIO ALPS Medical Breakthroughs ETF

-0.53 (-1.31%)

USD 0.13B
XHS SPDR® S&P Health Care Service..

-1.07 (-1.10%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.09 (-0.29%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.44 (-0.67%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-1.84%)

USD 0.01B

ETFs Containing PJP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.95% 90% A- 64% D
Dividend Return 0.76% 56% F 11% F
Total Return 15.72% 90% A- 60% D-
Trailing 12 Months  
Capital Gain 24.56% 57% F 67% D+
Dividend Return 1.10% 56% F 12% F
Total Return 25.66% 62% D 63% D
Trailing 5 Years  
Capital Gain 43.74% 76% C+ 67% D+
Dividend Return 5.68% 61% D- 14% F
Total Return 49.42% 71% C- 63% D
Average Annual (5 Year Horizon)  
Capital Gain 6.88% 76% C+ 58% F
Dividend Return 7.46% 71% C- 53% F
Total Return 0.57% 58% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 13.14% 76% C+ 71% C-
Risk Adjusted Return 56.72% 86% B+ 73% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike